Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer
The objective of this study is to evaluate the efficacy and safety of radiation therapy combined with anti-PD-1 antibody SHR-1210 in patients with esophageal cancer
Esophageal Neoplasms|Esophageal Diseases|Esophageal Squamous Cell Carcinoma
DRUG: Radiation|DRUG: SHR-1210
Objective response rate (ORR), ORR was evaluated 4-8 weeks after completion of RT and was recorded according to RECIST, version 1.1., 4-8 weeks
Treatment-emergent adverse events, Incidence of treatment-emergent adverse events would be assessed based on the common toxicity criteria for adverse events version 4.0 (CTCAE v4.0) and EORTC criterion., year 0 - year 1|Local-regional free survival (LRFS), LRFS was calculated from the date of treatment initiation to the date of documented failure., year 0 - year 3|Overall survival, OS was determined as the time (in months) between the first day of therapy and the last follow-up or the date of death., year 0 - year 3|Health-related quality of life (HRQoL), HRQoL measured by standardized EORTC questionaires (EORTC QLQ-C30), From baseline to one year after RT.|Health-related quality of life (HRQoL), HRQoL measured by standardized EORTC questionaires (EORTC QLQ-OES18), From baseline to one year after RT.
The objective of this study is to evaluate the efficacy and safety of radiation therapy combined with anti-PD-1 antibody SHR-1210 in patients with esophageal cancer